News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

All Stories

Exciting new CRISPR-CasX variant could be ‘Swiss army knife’ for genetics

February 5, 2019

Silicon Republic

Exciting new CRISPR-CasX variant could be ‘Swiss army knife’ for genetics

February 5, 2019

Silicon Republic

Future of Epigenetic Medicine

July 22, 2024

FutureBites

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR technology’s next wave: Eight companies to watch in 2024

June 20, 2024

Labiotech

Top Five Privately Held Gene Editing Therapy Companies

May 31, 2024

Genetic Engineering & Biotechnology News

Women @ RopesTalk: Conversation with Svetlana Lucas, Scribe Therapeutics

May 22, 2024

Ropes & Gray

DNA: Cutting the Future of Genome Editing

May 2, 2024

The Biomedical Scientist

Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology

December 20, 2023

Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases

July 17, 2023

Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June

May 22, 2023

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 19, 2023

Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases

May 16, 2023

Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 2, 2023

Publications and presentations

Scribe Corporate Deck 2025 Q1

February 3, 2025

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature